ABX 464

Drug Profile

ABX 464

Alternative Names: ABX-464

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Splicos
  • Developer Abivax
  • Class Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections; Ulcerative colitis

Most Recent Events

  • 01 Oct 2017 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in Belgium (PO) (NCT03093259)
  • 23 Jul 2017 Efficacy and safety data from a phase IIa trial in HIV infections released by Abivax
  • 01 Jun 2017 Abivax completes a phase II trial in HIV infections (Adjunctive treatment; Treatment-experienced) in Belgium, France and Spain (PO) (NCT02735863)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top